Clinical trials: Respiratory Disorder
Coronavirus Disease 2019 (COVID-19)
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
CSL760 is a human hyperimmune product of the purified gamma immunoglobulin (IgG) fraction of human plasma containing polyvalent neutralizing antibodies to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
- Trial name
- NCT04638634
- Testing
- CSL760
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Trial name
- NCT00064402
- Testing
- arformoterol tartrate inhalation solution, Salmeterol
- Where
- 65 sites in United States
- Volunteers
- 741 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
Prevention of Asthma Relapse After Discharge From Emergency
The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room
- Trial name
- PARADE (NCT00326053)
- Testing
- Budesonide/formoterol
- Where
- 20 sites in Canada
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
COVID-19
The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin
This study is a multi-center, randomized, double blinded, prospective, placebo controlled study. Patients upon diagnosis of COVID-19 (Corona Virus Disease-19) will be eligible to participate in the study.
- Trial name
- NCT04601077
- Testing
- Nitric Oxide lozenges, 30 mg
- Where
- United States
- Volunteers
- 524 people
- Sponsor
- Nitric Oxide Innovations LLC
Asthma
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with…
- Trial name
- NCT02918019
- Testing
- MSTT1041A
- Where
- 138 sites in United States, Argentina and 13 more
- Volunteers
- 517 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong
This is a randomized, double-blinded, Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate to evaluate the changes in…
- Trial name
- NCT05254236
- Testing
- COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose), COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Seasonal Allergic Rhinitis
Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation
The objective of this study is to evaluate the clinical equivalence of the test formulation of mometasone furoate anhydrous 50 mcg/actuation nasal spray (manufactured by Teva Pharmaceutical Industries, Ltd.
- Trial name
- NCT01523236
- Testing
- Mometasone furoate, Nasonex®
- Volunteers
- 800 people
- Sponsor
- Teva Pharmaceuticals USA
Nasal Congestion
Efficacy and Safety of Azeol Nasal Spray Versus Placebo in the Treatment of Early Symptoms of Common Cold in Adults
The main objective is to evaluate the efficacy of Azéol Spray Nasal, taken two times a day, versus placebo on nasal congestion in subject with common cold.
- Trial name
- EXSPRAY (NCT05159271)
- Testing
- Azeol spray nasal
- Where
- 2 sites in France
- Volunteers
- 144 people
- Sponsor
- Larena SAS
Asthma
Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing
Subjects will attend the unit for out-patient visits on Day 1, Day 7, Day 14 and Day 15 of each treatment period. The washout period between each treatment period will be a minimum of 10 days and maximum of 28 days.
- Trial name
- NCT00549744
- Testing
- GSK256066
- Where
- 3 sites in New Zealand, South Africa
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Nasal Congestion
Sonu Real-World Use Clinical Study to Treat Moderate to Severe Nasal Congestion
Real world utilization of Acoustic Resonance Therapy for symptoms of Nasal Congestion
- Trial name
- NCT06024564
- Testing
- Sonu Acoustic Resonance Therapy
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Third Wave Therapeutics
Asthma
Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506)
The aim of the study is to compare the efficacy of two doses of a fixed combination of ciclesonide/formoterol fumarate versus ciclesonide alone versus formoterol fumarate alone in patients with asthma.
- Trial name
- NCT00314509
- Testing
- Ciclesonide/Formoterol Combination
- Where
- 26 sites in France, Germany and 2 more
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers
The purpose of this study is to evaluate the effect of single doses of therapeutic and supratherapeutic doses of inhaled CHF 4226 pMDI on ventricular repolarization in healthy subjects compared with placebo.
- Trial name
- CT14 (NCT00777595)
- Testing
- CHF 4226 pMDI, Moxifloxacin
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Systemic Juvenile Idiopathic Arthritis
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
This was a phase III study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in Japanese patients with Systemic Juvenile…
- Trial name
- NCT02396212
- Testing
- Canakinumab
- Where
- 7 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Stage III NSCLC RWE in Chinese Patients
The objectives of this study are to assess molecular testing, treatment patterns and associated clinical outcomes in Chinese patients with treatment-naïve stage III non-small cell lung cancer (NSCLC) in real world setting.
- Trial name
- NCT04023812
- Where
- 25 sites in China
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT)
Evaluation of Soluble Fibrin in Thrombosis Exclusion
The purpose of the study is to evaluate the performances of Soluble Fibrin assay for exclusion of Pulmonary Embolism and Deep Venous Thrombosis.
- Trial name
- FSET (NCT02523937)
- Testing
- Soluble Fibrin
- Where
- France
- Volunteers
- 863 people
- Sponsor
- Diagnostica Stago R&D
Asthma and Rhinitis
A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies
GSK2245035 is a highly selective Toll-like receptor 7 (TLR7) agonist that stimulates preferentially the induction of type I interferons.
- Trial name
- NCT01607372
- Testing
- GSK2245035, Type 1 amber glass bottle
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Immunization, Healthy Volunteers
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
Primary Objective: To provide serum samples (collected from participants before vaccination [Blood Sample 1] and after final vaccination [Blood Sample 2]) to Center for Biologics Evaluation and Research (CBER) for further…
- Trial name
- NCT04551677
- Testing
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Adult Solid Tumor
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug…
- Trial name
- ANCERS-2 (NCT03253575)
- Testing
- CANscript
- Where
- 30 sites in United States
- Volunteers
- 800 people
- Sponsor
- Mitra RxDx, Inc.
Influenza
Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 2009 (swine flu) vaccine in healthy young children
- Trial name
- NCT00996307
- Testing
- MF59-eH1N1_f
- Where
- 29 sites in United States, Mexico
- Volunteers
- 654 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Asthma
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers
The study is performed to evaluate the total systemic exposure and lung bioavailability of CHF 5993 pMDI combination, in healthy volunteers subjects.
- Trial name
- NCT02359292
- Testing
- CHF 5993 HS 200/6/25 pMDI, CHF 5993 MS 100/6/25 pMDI, CHF 5993 HS 200/6/25 pMDI + Charcoal Block
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.